Comprehensive Stock Comparison
Compare Synlogic, Inc. (SYBX) vs Theriva Biologics, Inc. (TOVX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety |  TOVX | Beta 0.80 vs SYBX's 0.97 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) |  SYBX | -55.0% vs TOVX's -85.9% |
| Efficiency (ROA) | SYBX | -19.5% ROA vs TOVX's -84.9%, ROIC -205.7% vs -142.7% |
Who Each Stock Is For
Income & stability
TOVXbeta 0.80
Growth exposure
SYBXRev growth -99.8%, EPS growth 78.2%, 3Y rev CAGR -83.4%
Long-term compounding (10Y)
SYBX-97.9% 10Y total return vs TOVX's -100.0%
Sleep-well-at-night portfolio
TOVXLower volatility, beta 0.80, Low D/E 8.2%, current ratio 2.15x
Defensive / Recession hedge
TOVXBeta 0.80, current ratio 2.15x
Business Model
What each company does and how it makes money
Synlogic is a clinical-stage biopharmaceutical company developing synthetic biotic medicines — engineered probiotics — to treat metabolic and immunological diseases. It generates revenue primarily through research collaborations and milestone payments from partners like Roche, with potential future income from drug sales if its pipeline succeeds. The company's key advantage lies in its proprietary platform for engineering bacterial strains to perform therapeutic functions in the gut — a novel approach distinct from traditional small molecules or biologics.
Theriva Biologics is a clinical-stage biopharmaceutical company developing novel therapeutics for diseases with high unmet medical need, particularly in oncology and gastrointestinal disorders. It generates revenue primarily through research collaborations and licensing agreements — though as a pre-revenue clinical-stage company, it currently relies on equity financing and grants to fund operations. The company's competitive advantage lies in its proprietary platform technologies for developing targeted biologics and its focus on niche therapeutic areas where existing treatments are inadequate.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
SYBX 2TOVX 0SYBX5/7 metricsSYBX5/6 metricsSYBX leads in 2 of 6 categories — strongest in Profitability & Efficiency and Total Returns. 2 categories are tied.
Financial Metrics (TTM)
SYBX and TOVX operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | SYBXSynlogic, Inc. | TOVXTheriva Biologics… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$3M | -$26M |
| Net IncomeAfter-tax profit | -$3M | -$26M |
| Free Cash FlowCash after capex | -$4M | -$19M |
| Gross MarginGross profit ÷ Revenue | +100.0% | — |
| Operating MarginEBIT ÷ Revenue | -5118.8% | — |
| Net MarginNet income ÷ Revenue | -2919.9% | — |
| FCF MarginFCF ÷ Revenue | -3959.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | +93.4% |
Valuation Metrics
| Metric | SYBXSynlogic, Inc. | TOVXTheriva Biologics… |
|---|---|---|
| Market CapShares × price | $7M | $2M |
| Enterprise ValueMkt cap + debt − cash | -$12M | -$8M |
| Trailing P/EPrice ÷ TTM EPS | -0.31x | -0.01x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 862.80x | — |
| Price / BookPrice ÷ Book value/share | 0.56x | 0.01x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
SYBX delivers a -31.3% return on equity — every $100 of shareholder capital generates $-31 in annual profit, vs $-4 for TOVX. On the Piotroski fundamental quality scale (0–9), SYBX scores 2/9 vs TOVX's 1/9, reflecting mixed financial health.
| Metric | SYBXSynlogic, Inc. | TOVXTheriva Biologics… |
|---|---|---|
| ROE (TTM)Return on equity | -31.3% | -3.9% |
| ROA (TTM)Return on assets | -19.5% | -84.9% |
| ROICReturn on invested capital | -2.1% | -142.7% |
| ROCEReturn on capital employed | -120.6% | -69.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 |
| Debt / EquityFinancial leverage | — | 0.08x |
| Net DebtTotal debt minus cash | -$19M | -$10M |
| Cash & Equiv.Liquid assets | $19M | $12M |
| Total DebtShort + long-term debt | $0 | $2M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (with DRIP)
A $10,000 investment in SYBX five years ago would be worth $127 today (with dividends reinvested), compared to $13 for TOVX. Over the past 12 months, SYBX leads with a -55.0% total return vs TOVX's -85.9%. The 3-year compound annual growth rate (CAGR) favors SYBX at -61.1% vs TOVX's -79.5% — a key indicator of consistent wealth creation.
| Metric | SYBXSynlogic, Inc. | TOVXTheriva Biologics… |
|---|---|---|
| YTD ReturnYear-to-date | -49.6% | -29.3% |
| 1-Year ReturnPast 12 months | -55.0% | -85.9% |
| 3-Year ReturnCumulative with dividends | -94.1% | -99.1% |
| 5-Year ReturnCumulative with dividends | -98.7% | -99.9% |
| 10-Year ReturnCumulative with dividends | -97.9% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -61.1% | -79.5% |
Risk & Volatility
TOVX is the less volatile stock with a 0.80 beta — it tends to amplify market swings less than SYBX's 0.97 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SYBX currently trades 30.1% from its 52-week high vs TOVX's 12.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SYBXSynlogic, Inc. | TOVXTheriva Biologics… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.97x | 0.80x |
| 52-Week HighHighest price in past year | $1.96 | $1.50 |
| 52-Week LowLowest price in past year | $0.54 | $0.16 |
| % of 52W HighCurrent price vs 52-week peak | +30.1% | +12.3% |
| RSI (14)Momentum oscillator 0–100 | 35.3 | 51.9 |
| Avg Volume (50D)Average daily shares traded | 116K | 11.3M |
Analyst Outlook
| Metric | SYBXSynlogic, Inc. | TOVXTheriva Biologics… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Mar 26 | Change |
|---|---|---|---|
| Synlogic, Inc. (SYBX) | 100 | 1.79 | -98.2% |
| Theriva Biologics, … (TOVX) | 100 | 0.17 | -99.8% |
Synlogic, Inc. (SYBX) returned -99% over 5 years vs Theriva Biologics, … (TOVX)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Synlogic, Inc. (SYBX) | $0.00 | $8000.00 | — |
| Theriva Biologics, … (TOVX) | $0.00 | $0.00 | — |
Synlogic, Inc.'s revenue grew from $0M (2015) to $0M (2024) — a 0.0% CAGR. Theriva Biologics, Inc.'s revenue grew from $0M (2015) to $0M (2024) — a 0.0% CAGR.
Chart 3EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Synlogic, Inc. (SYBX) | -34.9 | -1.92 | +94.5% |
| Theriva Biologics, … (TOVX) | -189.68 | -19.03 | +90.0% |
Synlogic, Inc.'s EPS grew from $-34.90 (2015) to $-1.92 (2024). Theriva Biologics, Inc.'s EPS grew from $-189.68 (2015) to $-19.03 (2024).
Chart 4Free Cash Flow — 5 Years
Synlogic, Inc. generated $-32M FCF in 2024 (+40% vs 2021). Theriva Biologics, Inc. generated $-17M FCF in 2024 (-31% vs 2021).
SYBX vs TOVX: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — SYBX or TOVX?
Over the past 5 years, Synlogic, Inc. (SYBX) delivered a total return of -98.7%, compared to -99.9% for Theriva Biologics, Inc. (TOVX). A $10,000 investment in SYBX five years ago would be worth approximately $127 today (assuming dividends reinvested). Over 10 years, the gap is even starker: SYBX returned -97.9% versus TOVX's -100.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — SYBX or TOVX?
By beta (market sensitivity over 5 years), Theriva Biologics, Inc. (TOVX) is the lower-risk stock at 0.80β versus Synlogic, Inc.'s 0.97β — meaning SYBX is approximately 22% more volatile than TOVX relative to the S&P 500.
03Which has better profit margins — SYBX or TOVX?
Theriva Biologics, Inc. (TOVX) is the more profitable company, earning 0.0% net margin versus -2919.9% for Synlogic, Inc. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TOVX leads at 0.0% versus -5118.8% for SYBX. At the gross margin level — before operating expenses — SYBX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — SYBX or TOVX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is SYBX or TOVX better for a retirement portfolio?
For long-horizon retirement investors, Theriva Biologics, Inc. (TOVX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.80)). Both have compounded well over 10 years (TOVX: -100.0%, SYBX: -97.9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between SYBX and TOVX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.